Pharma and Irish inversions: Increasing your share price

May 31 2014

A spate of recent examples indicates that inversion transactions are as popular as they have ever been, with Pfizer’s attempted deal with AstraZeneca highlighting that companies in the pharmaceuticals industry are increasingly using the inversion option. William Fry Tax Advisors, the Irish member firm of Taxand, look at why this is, and analyse why Ireland is proving to be the location of choice for newly-formed companies post-inversion.

Unlock this content.

The content you are trying to view is exclusive to our subscribers.

To unlock this content:

Take a Free Trial or Login

Topics

more across site & shared bottom lb ros

More from across our site

Direct Tax

Washington DC Capitol view on cloudy sky background

A big, beautiful analysis of the One Big Beautiful Bill

The flagship 2025 tax legislation has sprawling implications for multinationals, including changes to GILTI and foreign-derived intangible income. Barry Herzog of HSF Kramer assesses the impact

Barry Herzog, January 16 2026

Direct Tax

Oslo, Norway - 24 September 2022: PricewaterhouseCoopers or PWC

PwC Middle East announces leadership transition

Hani Ashkar, after more than 12 years leading PwC in the region, is set to be replaced by Laura Hinton

Sam Sholli, January 16 2026

Direct Tax

Treasury has released final and proposed BEAT regulations

A taxing week: Solution for tax agent regulator not a solution for all

With the three-year anniversary of the PwC tax scandal approaching, it’s time to take stock of how tax agent regulation looks today

Tom Ravlic, January 16 2026

Direct Tax

Pillar two is revising global tax competition with a 15% minimum tax rate

This week in tax: Businesses should prepare for pillar two disputes, firm warns

Rolling out the global minimum tax has increased complexity, according to Baker McKenzie; in other news, Donald Trump has announced a 25% tariff on countries doing business with Iran

Sam Sholli, January 16 2026

Transfer Pricing